argenx (ARGX) Q3 2026 Earnings Call Transcript

argenx reported Q3 2026 product net sales of $1.7 billion, up 54% year over year and 13% quarter over quarter, with operating profit of $486 million and a 28% margin (37% excluding $150 million in Forte transaction costs). The company ended the quarter with $3.7 billion in cash after paying a net $2.1 billion for Forte, and now expects 2026 R&D and SG&A expenses of approximately $4 billion. Management highlighted five potential U.S. launches in 2027 and expects 10 molecules in clinical development by year-end, while noting the DM ALKIVIA trial missed its primary endpoint and requires an additional registrational study.

Analysis

ARGX’s main near-term valuation hinge is not the current growth rate but whether VYVGART can keep converting label expansion into durable patient adds while the company funds several launches and a broader pipeline. The seronegative “halo” could lower physician friction across MG, but it is a company-reported commercial read-through; verify through subsequent indication-level patient and prescription trends, not access coverage alone. More launches also mean greater field-force, inventory, and payer-support demands, so revenue growth may not translate into near-term margin expansion.

The December EMPASSION readout is the clearest 1–3 month catalyst and a genuine binary risk: non-inferiority to IVIg could support adoption on convenience, but does not by itself establish superior outcomes or a rapid switch from entrenched treatment. Any 2027 launch also faces payer-policy lag. Over 6–18 months, IMNM and other label expansions could broaden the franchise, while the DM endpoint miss and Sjögren’s futility underscore that pipeline breadth should not be valued as probability-adjusted certainty. Forte/FB102 adds upside optionality, but Phase III design, execution, and commercial relevance remain to be demonstrated. The key falsifiers are a failed or equivocal MMN readout, slowing MG/CIDP patient additions, or expenses rising faster than revenue for multiple quarters.

Key Decisions for Investors

• Avoid chasing ARGX on the quarter alone; initiate only a measured position ahead of the December EMPASSION catalyst if event volatility is acceptable. Prefer defined-risk call spreads over outright calls, and size for a binary clinical outcome; do not assume non-inferiority guarantees rapid uptake.
• For investors already long, consider trimming into strength or hedging part of the position through the MMN readout. Reassess after the full data, including the prespecified endpoint, safety, and IVIg-arm performance—not management’s characterization of the result.
• Track quarterly MG/CIDP patient adds and revenue alongside operating expenses. A sustained deterioration in patient growth or expenses outpacing sales would weaken the operating-leverage thesis; payer coverage percentages alone are insufficient confirmation of demand.
• Treat the 2027 launch slate and FB102 as upside options, not base-case earnings. Revisit estimates after regulatory decisions, payer-policy formation, and disclosure of FB102 Phase III design; the DM setback argues against assigning high certainty to unconfirmed indications.